3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
22
Melanoma
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Colorectal Neoplasms
6
Uterine Cervical Neoplasms
3
Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Breast Neoplasms, Male
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Transitional Cell
2
Uveal Melanoma
1
Turcot syndrome
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Recurrence
1
Rectal Neoplasms
1
Interventions
pembrolizumab
24
Paclitaxel
11
Carboplatin
11
Trastuzumab
9
Nivolumab
7
Fulvestrant
6
palbociclib
4
olaparib
4
Taxes
4
Surveys and Questionnaires
4
Methods
4
Early Intervention, Educational
4
Docetaxel
4
Cyclophosphamide
4
Biopsy
4
Bevacizumab
4
pertuzumab
3
lenvatinib
3
fludarabine
3
atezolizumab
3
abemaciclib
3
Tamoxifen
3
Specimen Handling
3
Psychiatric Rehabilitation
3
Metformin
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Interviews as Topic
3
Gemcitabine
3
Counseling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Interleukin-2
×
Breast
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled